🇺🇸 FDA
Pipeline program

Sar444671 placebo - matched placebo for test, Rilzabrutinib

EFC17872

Phase 3 small_molecule active

Quick answer

Sar444671 placebo - matched placebo for test, Rilzabrutinib for Blood and lymphatic diseases is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Blood and lymphatic diseases
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials